New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 5, 2010, Pages 1142-1144

  Colaizzo, D ^a   Tiscia, G L ^a   Pisanelli, D ^a   Bafunno, V ^b   Amitrano, L ^c   Grandone, E ^a   Guardascione, M A ^c   Margaglione, M ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

AGED; BONE MARROW CANCER; CLINICAL ARTICLE; GENE; GENE LOCUS; GENE MUTATION; HUMAN; LETTER; MALE; MYELOPROLIFERATIVE NEOPLASM; NEOPLASM; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; TET2 GENE; VEIN THROMBOSIS; GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDER; THROMBOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DNA-BINDING PROTEINS; HUMANS; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS; SPLANCHNIC CIRCULATION; THROMBOSIS;

EID: 77953753005     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03810.x     Document Type: Letter

References (10)

1. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23:905-11.
2. Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C, Delannoy A, Devidas A, Gardembas-Pain M, Isnard F, Plumelle Y, Bernard O, Vainchenker W, Najman A, Bellanné-Chantelot C. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009, 114:1628-32.
3. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, Van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-42.
4. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113:6403-10.
5. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-301.
6. Polycythemia vera: the natural history of 1,213 patients followed for 20 years. Ann Intern Med 1995, 123:656-64.
7. Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol 2004, 41:10-14.
8. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004, 117:755-61.
9. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14-22.
10. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007, 5:55-61.